Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression

Biochemical and Biophysical Research Communications

Volumn 380, Issue 2, 2009, Pages 236-242

  Chang, Charn Jung ^a   Hsu, Chuan Chih ^a,b   Yung, Ming Chi ^c,e   Chen, Kai Yun ^a   Tzao, Ching ^a   Wu, Wei Fong ^d,e   Chou, Hsiang Yun ^e,f   Lee, Yi Yen ^d,e   Lu, Kai Hsi ^e   Chiou, Shih Hwa ^e,f   Ma, Hsin I ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c TAIPEI CITY HOSPITAL   (Taiwan)

^d Hospital   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

CD133; Glioblastoma; Radiotherapy; SirT1

Indexed keywords

CD133 ANTIGEN; LENTIVIRUS VECTOR; SIRTUIN 1;

ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; EMBRYONIC STEM CELL; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SURVIVAL RATE; TUMOR GROWTH;

ANTIGENS, CD; APOPTOSIS; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; GLIOMA; GLYCOPROTEINS; HUMANS; PEPTIDES; RADIATION TOLERANCE; SIRTUINS;

MUS; MUS MUSCULUS;

EID: 60349085855     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.01.040     Document Type: Article

References (30)

1. Stupp R., Mason W.P., van den Bent M.J., Weller M., Fisher B., Taphoorn M.J., and Belanger K. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352 (2005) 987-996
2. Jordan C.T., Guzman M.L., and Noble M. Cancer stem cells. N. Engl. J. Med. 355 (2006) 1253-1261
3. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., and Dirks P.B. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401
4. Mizrak D., Brittan M., and Alison M.R. CD133: molecule of the moment. J. Pathol. 214 (2008) 3-9
5. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., and De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 445 (2007) 111-115
6. Miki J., Furusato B., Li H., Gu Y., and Rhim J.S. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res. 67 (2007) 3153-3161
7. Ma S., Chan K.W., Hu L., and Guan X.Y. Identification and characterization of tumorigenic liver cancer stem cells. Gastroenterology 132 (2007) 2542-2556
8. Zeppernick F., Ahmadi R., Campos B., and Herold-Mende C.C. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin. Cancer Res. 14 (2008) 123-129
9. Beier D., Wischhusen J., Dietmaier W., Hau P., and Beier C.P. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol. 18 (2008) 370-377
10. Bao S., Wu Q., McLendon R.E., Hao Y., Bigner D.D., and Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
11. Lee J., Kotliarova S., Kotliarov Y., Li A., Park J.K., and Fine H.A. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9 (2006) 391-403
12. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., and Weinberg R.A. HSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107 (2001) 149-159
13. Saunders L.R., and Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26 (2007) 5489-5504
14. Wang C., Chen L., Hou X., Li Z., Kabra N., Ma Y., Nemoto S., Finkel T., Gu W., Cress W.D., and Chen J. Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage. Nat. Cell Biol. 8 (2006) 1025-1031
15. Potente M., Ghaeni L., Baldessari D., Mostoslavsky R., Rossig L., Dequiedt F., Haendeler J., Mione M., Dejana E., Alt F.W., Zeiher A.M., and Dimmeler S. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 21 (2007) 2644-2658
16. Ford J., Jiang M., and Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 65 (2005) 10457-10463
17. Sun Y., Sun D., Li F., Tian L., Li C., and Wang S. Downregulation of SirT1 by antisense oligonucleotides induces apoptosis and enhances radiation sensitization in A549 lung cancer cells. Lung Cancer 58 (2007) 21-29
18. Chiou S.H., Kao C.L., Chen Y.W., Ku H.H., Hsu M.T., and Wong T.T. Identification of CD133-positive radioresistant cells in atypical teratoid/rhabdoid tumor. PLoS ONE 3 5 (2008) e2090
19. Kojima K., Ohhashi R., Fujita Y., and Ito M. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem. Biophys. Res. Commun. 373 (2008) 423-428
20. Ben-Porath I., Thomson M.W., Carey V.J., Ge R., Bell G.W., Regev A., and Weinberg R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40 (2008) 499-507
21. Huffman D.M., Grizzle W.E., Bamman M.M., and Nagy T.R. SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res. 67 (2007) 6612-6618
22. Yamakuchi M., Ferlito M., and Lowenstein C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. USA 105 (2008) 13421-13426
23. Fujita Y., Kojima K., Hamada N., Ohhashi R., and Ito M. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem. Biophys. Res. Commun. 377 (2008) 114-119
24. Chu F., Chou P.M., Zheng X., and Rebbaa A. Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene SirT1. Cancer Res. 65 (2005) 10183-10187
25. Y. Zhang, M. Zhang, H. Dong, X. Zhang, Deacetylation of cortactin by SIRT1 promotes cell migration, Oncogene (2008) (Epub ahead of print).
26. Wang R.H., Zheng Y., Kim H.S., Finkel T., and Deng C.X. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol. Cell 32 (2008) 11-20
27. Wang R.H., Sengupta K., Li C., Kim H.S., Wang X.W., Ried T., and Deng C.X. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14 (2008) 312-323
28. Ashraf N., Zino S., Macintyre A., Kingsmore D., and Shiels P.G. Altered sirtuin expression is associated with node-positive breast cancer. Br. J. Cancer 95 (2006) 1056-1061
29. Inoue T., Hiratsuka M., Osaki M., Nakano S., Katoh M., Ito H., and Oshimura M. SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress. Oncogene 26 (2007) 945-957
30. Matsushita N., Takami Y., Kimura M., Nakayama T., and Takata M. Role of NAD-dependent deacetylases SIRT1 and SIRT2 in radiation and cisplatin-induced cell death in vertebrate cells. Genes Cells 10 (2005) 321-332